CAPTRUST Financial Advisors
AMLX icon

CAPTRUST Financial Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,561
Closed -$288K – 2158
2023
Q4 		$288K Sell
19,561
-13,469
-41% -$206K ﹤0.01% 2139
2023
Q3 		$605K Sell
33,030
-483
-1% -$10.2K ﹤0.01% 1521
2023
Q2 		$723K Buy
+33,513
New +$905K ﹤0.01% 1411
2022
Q3 		– Sell
-19
Closed – – 2137
2022
Q2 		$0 Buy
+19
New +$226 ﹤0.01% 4920

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAPTRUST Financial Advisors's AMLX Position: Q1 2024 in Review

CAPTRUST Financial Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 19,561 shares — an estimated $288K sold.

CAPTRUST Financial Advisors first reported a position in AMLX in Q2 2022 and held it in 4 quarters. The position peaked at $723K in Q2 2023. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

  • CAPTRUST Financial Advisors reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 19,561 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $288K.
  • CAPTRUST Financial Advisors first reported a position in Amylyx Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's Amylyx Pharmaceuticals position peaked at $723K in Q2 2023.
  • 143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2024, filed 15 May 2024.